AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30965131
Drug: Psilocybin (315
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (315 μg/kg p.o.) during mindfulness retreat
Trial: 28508427
Drug: IQP-CL-101 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IQP-CL-101 (two softgels twice daily before main meals)
Trial: 28508427
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo twice daily before main meals)
Trial: 25453585
Drug: EE/GSD patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/GSD patch (0.55 mg ethinyl estradiol and 2.1 mg gestodene)
Trial: 25453585
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (0.02 mg ethinyl estradiol and 0.1 mg levonorgestrel)
Trial: 21801509
Drug: Five-element acupuncture
RxNorm normalized name: HISTA-FIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-element acupuncture treatment
Trial: 19500889
Drug: Clear carbohydrate
RxNorm normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear carbohydrate drink (CCD) (400 ml, 50 g carbohydrate, 0 g protein)
Trial: 19500889
Drug: Oral Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nutritional Supplement (ONS400) (70 g, 50 g carbohydrate, 15 g glutamine dissolved in water to a total volume of 400 ml)
Trial: 19500889
Drug: Oral Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nutritional Supplement (ONS300) (300 ml)
Trial: 17657595
Drug: Low quantities
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low quantities (2 g) of long chain lipid
Trial: 17657595
Drug: Medium chain
RxNorm normalized name: Medium chain triglyceride
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium chain lipid (2 g)
Trial: 17657595
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control formulation
Trial: 15118480
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg/d) and Alprazolam (1 mg/d)
Trial: 9181527
Drug: Ribavirin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (1000 mg per day) and IFN-alpha (3-6 million units thrice weekly)
Trial: 4039146
Drug: Carbocisteine granulate
RxNorm normalized name: carbocisteine
DrugBank: Carbocisteine (DB04339)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbocisteine granulate (750 mg)
Trial: 4039146
Drug: Carbocisteine capsules
RxNorm normalized name: carbocisteine
DrugBank: Carbocisteine (DB04339)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbocisteine capsules (750 mg)
Trial: 21048706
Drug: Dipeptidyl peptidase-4
RxNorm normalized name: Immature tripeptidyl-peptidase I
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dipeptidyl peptidase-4 (DPP-4) inhibitor
Trial: 21048706
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DPP-4 inhibitor and Metformin
Trial: 18372687
Drug: Daily artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily artificial gravity (AG) countermeasure treatment
Trial: 18372687
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no AG treatment)
Trial: 9453690
Drug: 0.375 mg
RxNorm normalized name: vitamin A 0.375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375 mg of sustained-release hyoscyamine twice a day
Trial: 9453690
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg doxazosin QHS
Trial: 9453690
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (hyoscyamine and doxazosin)
Trial: 8575234
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 to 8 mg once daily
Trial: 8575234
Drug: Metoprolol 25
RxNorm normalized name: metoprolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 25 to 62.5 mg twice daily
Trial: 31127269
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (three doses of 200 mg iron sucrose over 30 min on three separate days)
Trial: 31127269
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no intravenous iron)
Trial: 28939890
Drug: ELF-MF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELF-MF treatment for 45 minutes/day
Trial: 28939890
Drug: ELF-MF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELF-MF treatment for 120 minutes/day
Trial: 19290712
Drug: Hypothetical cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical cancer preventive treatment with one or two small side effects (beneficial or harmful)
Trial: 11678958
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of tacrolimus after an overnight fast
Trial: 11678958
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of tacrolimus 1 hour after breakfast
Trial: 11678958
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of tacrolimus after an overnight fast and 0.5 hours after breakfast (in 4 patients)
Trial: 9660327
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ethanol (LD)
Trial: 9660327
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ethanol (HD)
Trial: 29886915
Drug: Low-dose naloxone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naloxone infusion (0.5 μg/kg/h)
Trial: 29886915
Drug: High-dose naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose naloxone infusion (2.5 μg/kg/h)
Trial: 26364275
Drug: Huperzine A
RxNorm normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huperzine A (0.4 mg)
Trial: 26364275
Drug: Huperzine A
RxNorm normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huperzine A (0.8 mg)
Trial: 24159353
Drug: Pomegranate extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate extract (2g per day in 2 POMx pills)
Trial: 24159353
Drug: Placebo (pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (pills containing no pomegranate ingredients)
Trial: 12564608
Drug: Placebo (pressurized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (pressurized metered-dose inhaler)
Trial: 1888248
Drug: Diltiazem (sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (sustained release) 60 to 180 mg twice a day
Trial: 1888248
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 to 100 mg once a day
Trial: 1888248
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 to 20 mg once a day
Trial: 21122063
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three treatments
Trial: 28880931
Drug: Cardiac output
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac output goal directed therapy (GDT) algorithm
Trial: 25471599
Drug: WHEY (whey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHEY (whey protein solution)
Trial: 25471599
Drug: GEL (leucine-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEL (leucine-enriched whey protein gel)
Trial: 21823549
Drug: OM‐ER 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM‐ER 15 mg
Trial: 21823549
Drug: OM‐ER 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM‐ER 30 mg
Trial: 21823549
Drug: OC‐CR 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC‐CR 30 mg
Trial: 21823549
Drug: OC‐CR 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC‐CR 60 mg
Trial: 17181373
Drug: Rifamycin-based antituberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifamycin-based antituberculosis therapy
Trial: 17181373
Drug: Timing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing of HAART initiation after antituberculosis therapy
Trial: 2112165
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy with 2% mupirocin
Trial: 6416510
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (insulin A)
Trial: 6416510
Drug: Porcine insulin
RxNorm normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine insulin (insulin B)
Trial: 31216051
Drug: Repaglinide and
RxNorm normalized name: metformin and repaglinide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide and aspirin (without clopidogrel use)
Trial: 27240549
Drug: Cefuroxime administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime administered to mothers 15-60 minutes before Caesarean section
Trial: 16163743
Drug: Intervention by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention by mental health professional for treatment of depression
Trial: 12415443
Drug: Hypertonic saline/dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline/dextran solution (HSS group, n=13)
Trial: 9915292
Drug: Amino acid-based
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid-based dialysis solution
Trial: 7587846
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (multiple daily injections of insulin and glipizide)
Trial: 7587846
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin treatment (one morning injection per day)
Trial: 7587846
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (stepped approach to insulin therapy)
Trial: 2341068
Drug: Ceftriaxone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (single daily dose)
Trial: 2341068
Drug: Cefazolin and
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin and Gentamicin (combined therapy every 8 hours)
Trial: 7017488
Drug: Broncaspin (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broncaspin (1.2 g suppositories, twice a day for 14 days)
Trial: 7017488
Drug: Dimethylaminophenazone guaiacolglycolate
RxNorm normalized name: Dimethylaminophenazon
DrugBank: Aminophenazone (DB01424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethylaminophenazone guaiacolglycolate (commercial form, twice a day for 14 days)
Trial: 31094806
Drug: Meloxicam IV
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam IV (5-60 mg)
Trial: 27882910
Drug: Wii-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wii-therapy
Trial: 24917588
Drug: Daily muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily muscle manual stretching, passive articular mobilization, and palmar splint (Group B)
Trial: 24126211
Drug: HAC1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAC1 vaccine (90 μg non-adjuvanted)
Trial: 24126211
Drug: HAC1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAC1 vaccine (15 μg and 45 μg)
Trial: 24126211
Drug: Approved monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approved monovalent H1N1 vaccine
Trial: 22771827
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus sorafenib (gemcitabine 1000 mg/m² i.v., weekly seven times followed by 1 rest week, then weekly three times every 4 weeks plus sorafenib 200 mg, two tablets p.o., twice daily continuously)
Trial: 22771827
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus placebo (gemcitabine 1000 mg/m² i.v., weekly seven times followed by 1 rest week, then weekly three times every 4 weeks plus placebo, two tablets p.o., twice daily continuously)
Trial: 15361287
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg synthetic allitridum every day and 100 microg selenium every other day for one month each year from November 1989 to December 1991.
Trial: 15361287
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules containing corn oid.
Trial: 11550729
Drug: 5-session Preparing
RxNorm normalized name: Caviar Preparation
DrugBank: Caviar, unspecified (DB14241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-session Preparing for the Drug Free Years Program
Trial: 9786103
Drug: Clomipramine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 150 mg/day plus Nortriptyline 50 mg/day
Trial: 9786103
Drug: Clomipramine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 150 mg/day plus Placebo
Trial: 3555942
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (propranolol)
Trial: 21566299
Drug: Cinacalcet 30
RxNorm normalized name: cinacalcet 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet 30 mg daily with main meal, titrated monthly
Trial: 21566299
Drug: Cinacalcet 90
RxNorm normalized name: cinacalcet 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet 90 mg once weekly and 120 mg midweek with main meal, titrated monthly
Trial: 14732316
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (q8 hourly for 10 days)
Trial: 14732316
Drug: Clarithromycin (q12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (q12 hourly for 10 days)
Trial: 14732316
Drug: Cefprozil (q12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil (q12 hourly for 5 days)
Trial: 11497016
Drug: Steroid and/or
RxNorm normalized name: Corticosteroid and/or corticosteroid derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid and/or anapolan treatment (BMT-)
Trial: 7871339
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (doctors offered a WHO textbook on drug prescription and three monthly meetings with nurses and social workers)
Trial: 2829371
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg twice a day for 1 day
Trial: 2829371
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg twice a day for 2 days
Trial: 2829371
Drug: Oral ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ketoconazole and vaginal econazole nitrate (control)
Trial: 24961447
Drug: Kochujang (34.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kochujang (34.5 g/d)
Trial: 24198754
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg or 2 mg oromucosal nicotine spray
Trial: 24022237
Drug: Placebo oromucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oromucosal nicotine spray
Trial: 24198754
Drug: Nicotine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (1 mg or 2 mg)
Trial: 21624391
Drug: Rivastigmine 0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 0, 3, or 6 mg daily for six consecutive days
Trial: 14966574
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO) therapy at a pressure of 0.25 MPa
Trial: 10881250
Drug: Galantamine 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 32 mg/d
Trial: 10881250
Drug: Galantamine 24
RxNorm normalized name: galantamine 24 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 24 mg/d and 32 mg/d
Trial: 9008256
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Fosinopril + 12.5 mg Hydrochlorothiazide
Trial: 9008256
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Fosinopril + 12.5 mg Hydrochlorothiazide
Trial: 12959315
Drug: Pazinaclone (DN‐2327)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pazinaclone (DN‐2327) 4 mg
Trial: 12959315
Drug: Pazinaclone (DN‐2327)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pazinaclone (DN‐2327) 8 mg
Trial: 3611334
Drug: Neurodevelopmental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodevelopmental treatment (intensive physical therapy course for 6 weeks)
Trial: 27395413
Drug: Hypoxic confinement
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxic confinement combined with daily moderate-intensity exercise (HAMB)
Trial: 26248510
Drug: Low-dose rVSV-ZEBOV
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rVSV-ZEBOV (3×10^5 pfu)
Trial: 26248510
Drug: High-dose rVSV-ZEBOV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rVSV-ZEBOV (1×10^7 pfu or 5×10^7 pfu)
Trial: 12594139
Drug: Remifentanil (0.025,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.025, 0.05 and 0.1 micro g kg(‐1) min(‐1))
Trial: 10955754
Drug: Ambulatory oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory oxygen at 2 l min(‐1)
Trial: 8398588
Drug: R-verapamil 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-verapamil 500 mg
Trial: 8398588
Drug: R-verapamil 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-verapamil 1000 mg
Trial: 8398588
Drug: R-verapamil 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-verapamil 250 mg
Trial: 8398588
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg racemic verapamil
Trial: 3533370
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral nalmefene
Trial: 26606735
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily for 24 months plus ASA ≤100 mg for one month
Trial: 26606735
Drug: Conventional dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dual antiplatelet therapy (DAPT) with either ticagrelor or clopidogrel for 12 months plus ASA ≤100 mg for 24 months
Trial: 24276953
Drug: Aprepitant (day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (day 1: 125 mg; days 2-3: 80 mg)
Trial: 24276953
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (days 1-3: placebo)
Trial: 22774396
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with myo-inositol (MI) and D-chiro-inositol (DCI)
Trial: 15986825
Drug: Negative psychosocial
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative psychosocial factors (e.g., being a widower, divorced, low education, manual labor, pensioners, low social support)
Trial: 12865375
Drug: Self‐administered behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered behavioral treatment using a self‐help booklet (control condition)
Trial: 10369612
Drug: Fosinopril 10
RxNorm normalized name: fosinopril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 10 mg tablet
Trial: 10369612
Drug: HCTZ 12.5
RxNorm normalized name: HCTZ 12.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 12.5 mg tablet
Trial: 10369612
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet of fosinopril 10 mg plus HCTZ 12.5 mg
Trial: 10369612
Drug: Coadministered tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministered tablets of fosinopril 10 mg and HCTZ 12.5 mg